BACKGROUND: Diabetes mellitus is associated with an increased incidence of colorectal cancer, but the impact of diabetes mellitus on colorectal cancer prognosis is not clear. OBJECTIVE: We conducted a meta-analysis of observational studies to examine the association between preexisting diabetes mellitus and colorectal cancer all-cause mortality, cancer-specific mortality, and recurrence. DATA SOURCES: Medline and Embase were searched through August 22, 2012. STUDY SELECTION: We included studies reporting all-cause mortality, cancer-specific mortality, disease-free survival, or recurrence in patients who have colorectal cancer according to diabetic status. INTERVENTION: Meta-analyses were performed by the use of random-effects models. MAIN OUTCOME MEASURES: The primary outcomes measured were all-cause mortality, cancer-specific mortality, and disease-free survival. RESULTS: Twenty-six articles met our inclusion criteria. Patients with colorectal cancer who had diabetes mellitus had a 17% increased risk of all-cause mortality (relative risk, 1.17; 95% CI, 1.09-1.25) and a 12% increased risk of cancer-specific mortality (relative risk, 1.12; 95% CI, 1.01-1.24) in comparison with those who did not have diabetes mellitus. Those with diabetes mellitus also had poorer disease-free survival (relative risk, 1.54; 95% CI, 1.08-2.18) compared with their nondiabetic counterparts. In subgroup analyses, diabetes mellitus was associated with all-cause mortality in both rectal (relative risk, 1.24; 95% CI, 1.07-1.29) and colon cancer patients (relative risk, 1.17; 95% CI, 1.07-1.29). Sensitivity analyses including only patients with nonmetastatic disease identified stronger associations between diabetes mellitus and both all-cause (relative risk, 1.32; 95% CI, 1.21-1.44) and cancer-specific (relative risk, 1.27; 95% CI, 1.06-1.52) mortality. LIMITATIONS: Some studies had short follow-up or did not report mean or median follow-up. The included studies were heterogeneous in study population, diabetes mellitus diagnostic criteria, and outcome ascertainment. CONCLUSION: Patients with colorectal cancer who have diabetes mellitus are at greater risk for all-cause and cancer-specific mortality and have worse disease-free survival than those who do not have diabetes mellitus. Studies are warranted to determine whether the proper treatment could attenuate the excess mortality among patients with colorectal cancer who have diabetes mellitus.
BACKGROUND:Diabetes mellitus is associated with an increased incidence of colorectal cancer, but the impact of diabetes mellitus on colorectal cancer prognosis is not clear. OBJECTIVE: We conducted a meta-analysis of observational studies to examine the association between preexisting diabetes mellitus and colorectal cancer all-cause mortality, cancer-specific mortality, and recurrence. DATA SOURCES: Medline and Embase were searched through August 22, 2012. STUDY SELECTION: We included studies reporting all-cause mortality, cancer-specific mortality, disease-free survival, or recurrence in patients who have colorectal cancer according to diabetic status. INTERVENTION: Meta-analyses were performed by the use of random-effects models. MAIN OUTCOME MEASURES: The primary outcomes measured were all-cause mortality, cancer-specific mortality, and disease-free survival. RESULTS: Twenty-six articles met our inclusion criteria. Patients with colorectal cancer who had diabetes mellitus had a 17% increased risk of all-cause mortality (relative risk, 1.17; 95% CI, 1.09-1.25) and a 12% increased risk of cancer-specific mortality (relative risk, 1.12; 95% CI, 1.01-1.24) in comparison with those who did not have diabetes mellitus. Those with diabetes mellitus also had poorer disease-free survival (relative risk, 1.54; 95% CI, 1.08-2.18) compared with their nondiabetic counterparts. In subgroup analyses, diabetes mellitus was associated with all-cause mortality in both rectal (relative risk, 1.24; 95% CI, 1.07-1.29) and colon cancerpatients (relative risk, 1.17; 95% CI, 1.07-1.29). Sensitivity analyses including only patients with nonmetastatic disease identified stronger associations between diabetes mellitus and both all-cause (relative risk, 1.32; 95% CI, 1.21-1.44) and cancer-specific (relative risk, 1.27; 95% CI, 1.06-1.52) mortality. LIMITATIONS: Some studies had short follow-up or did not report mean or median follow-up. The included studies were heterogeneous in study population, diabetes mellitus diagnostic criteria, and outcome ascertainment. CONCLUSION:Patients with colorectal cancer who have diabetes mellitus are at greater risk for all-cause and cancer-specific mortality and have worse disease-free survival than those who do not have diabetes mellitus. Studies are warranted to determine whether the proper treatment could attenuate the excess mortality among patients with colorectal cancer who have diabetes mellitus.
Authors: Nicole Annette Shonka; James R Anderson; Amit W Panwalkar; Elizabeth C Reed; Preston D Steen; Apar Kishor Ganti Journal: Med Oncol Date: 2006 Impact factor: 3.064
Authors: Kelly B Stein; Claire F Snyder; Bethany B Barone; Hsin-Chieh Yeh; Kimberly S Peairs; Rachel L Derr; Antonio C Wolff; Frederick L Brancati Journal: Dig Dis Sci Date: 2010-07 Impact factor: 3.199
Authors: Brian M Wolpin; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Jennifer A Chan; Kana Wu; Michael N Pollak; Edward L Giovannucci; Charles S Fuchs Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati Journal: Lancet Date: 2011-06-24 Impact factor: 79.321
Authors: NaNa Keum; Chen Yuan; Reiko Nishihara; Emilie Zoltick; Tsuyoshi Hamada; Alejandro Martinez Fernandez; Xuehong Zhang; Akiko Hanyuda; Li Liu; Keisuke Kosumi; Jonathan A Nowak; Iny Jhun; T Rinda Soong; Teppei Morikawa; Fred K Tabung; Zhi Rong Qian; Charles S Fuchs; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Shuji Ogino; Edward L Giovannucci; Kana Wu Journal: Int J Cancer Date: 2017-03-28 Impact factor: 7.396
Authors: Andrea Martisova; Lucia Sommerova; Katarina Kuricova; Jan Podhorec; Borivoj Vojtesek; Katerina Kankova; Roman Hrstka Journal: Oncol Lett Date: 2019-09-04 Impact factor: 2.967
Authors: Brendan J Guercio; Kaori Sato; Donna Niedzwiecki; Xing Ye; Leonard B Saltz; Robert J Mayer; Rex B Mowat; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Alan Venook; Frank B Hu; Shuji Ogino; Kana Wu; Walter C Willett; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544
Authors: Claudio Vernieri; Fabio Galli; Laura Ferrari; Paolo Marchetti; Sara Lonardi; Evaristo Maiello; Rosario V Iaffaioli; Maria G Zampino; Alberto Zaniboni; Sabino De Placido; Maria Banzi; Azzurra Damiani; Daris Ferrari; Gerardo Rosati; Roberto F Labianca; Paolo Bidoli; Giovanni L Frassineti; Mario Nicolini; Lorenzo Pavesi; Maria C Tronconi; Angela Buonadonna; Sabrina Ferrario; Giovanni Lo Re; Vincenzo Adamo; Emiliano Tamburini; Mario Clerico; Paolo Giordani; Francesco Leonardi; Sandro Barni; Andrea Ciarlo; Luigi Cavanna; Stefania Gori; Saverio Cinieri; Marina Faedi; Massimo Aglietta; Maria Antista; Katia F Dotti; Francesca Galli; Maria Di Bartolomeo Journal: Oncologist Date: 2019-01-03
Authors: Jessica K Paulus; Christina D Williams; Furha I Cossor; Michael J Kelley; Robert E Martell Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-05 Impact factor: 4.254